Open Access1016 Lusutrombopag Is a Safe Treatment Option for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Invasive Procedure: Pooled Safety Analysis From 3 Studies
Author(s) -
Robert S. Brown,
Namiki Izumi,
Takeshi Kano,
Toshimitsu Ochiai,
Masayuki Kurosaki,
Francesco Violi,
Pomy Shrestha
Publication year - 2019
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000593600.52978.78
Subject(s) - medicine , placebo , adverse effect , randomization , chronic liver disease , thrombopoietin receptor , population , surgery , randomized controlled trial , thrombopoietin , cirrhosis , pathology , alternative medicine , stem cell , environmental health , haematopoiesis , biology , genetics